Transgenic IL-2 expression in Ewing tumor cell lines after transfection with starburst dendrimers and cationic liposomes

Pediatric Hematology and Oncology

Volumn 19, Issue 7, 2002, Pages 509-520

  Ackermann, Birgit ^a   Engel, Barbara C ^a   Buttlies, Barbara ^a   Zibert, Andree ^a   Burdach, Stefan ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Ewing tumor; Gene therapy; IL 2; Liposomes; Starburst dendrimer

Indexed keywords

DENDRIMER; INTERLEUKIN 2; LIPOFECTAMINE; LIPOSOME; STARBURST DENDRIMER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EWING SARCOMA; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONVIRAL GENE DELIVERY SYSTEM; TRANSGENICS;

CATIONS; FIBROBLASTS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LIPOSOMES; POLYAMINES; SARCOMA, EWING'S; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036786022     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010290097332     Document Type: Article

References (40)

1. Erard F, Corthesy P, Nabholz M, et al. Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors. J Immunol. 1985;134:1644-1652.
2. Mosmann TR, Coffman RL. Two types of mouse helper T-cell clones. Immunol Today. 1987;8:223-227.
3. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376.
4. Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2 activated lymphocytes. Annu Rev Immunol. 1986;4:681-709.
5. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of tumor interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA. 1989;86:9456-9460.
6. + cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423-1431.
7. Asher A, Mule J, Kasid A, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-α. J Immunol. 1991;146:3227-3234.
8. Blankenstein T, Qin Z, Uberla K, et al. Tumor supression after tumor cell-targeted tumor necrosis factor α gene transfer. J Exp Med. 1991;173:1047-1052.
9. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by systemic administration of high-dose recombinant IL-2. J Exp Med. 1991;161:1169-1188.
10. Lotze M, Matory YL, Rayner AA, et al. Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer. 1986;58:2764-2772.
11. Oda K, Asao H, Higuchi M, et al. Induction of IL-1 beta-converting enzyme-independent apoptosis by IL-2 in human T cell lines. Int Immunol. 1997;9:1303-1310.
12. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
13. Bubenik J, Simova J, Jandlova T. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett. 1990;23:287-292.
14. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T-helper function in the generation of anti-tumor response. Cell. 1990;60:397-403.
15. Sobol RE, Royston I, Fakhrai H, et al. Injection of colon carcinoma patients with autologus irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study. Hum Gene Ther. 1995;6:195-204.
16. Osanto S, Brouwenstein N, Vaessen N, et al. Immunization with interleukin-2 transfected melanoma cells: a phase I-II study in patients with metastatic melanoma. Hum Gene Ther. 1993;4:323-333.
17. Dilloo D, Bacon K, Holden W, et al. Combined chemokine and cytokine gene transfer enhances anti-tumor immunity. Nat Med. 1996;2:1090-1095.
18. Shawler DL, Dorigo O, Gjerset RA, et al. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J Immunother Emphasis Tumor Immunol. 1995;17:201-208.
19. Zier KS, Salvadori S, Cronin KC, et al. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness. Cancer Gene Ther. 1994;1:43-50.
20. Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med. 1993;177:1127-1134.
21. Yoshida H, Enomoto H, Tagawa M, et al. Impaired tumorigenicity and decreased liver metastasis of murine neuroblastoma cells engineered to secrete interleukin-2 or granulocyte macrophage colonystimulating factor. Cancer Gene Ther. 1998;5:67-73.
22. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1998;9:2805-2852.
23. Hernandez A, Zöller K, Enczmann J, et al. Differential transfection efficiency rates of the GM-CSF gene into human renal cell carcinoma lines by lipofection. Cancer Gene Ther. 1997;4:59-65.
24. Chen X, Li Y, Xiong K, et al. A novel nonviral cytoplasmic gene expression system and its implications in cancer gene therapy. Cancer Gene Ther. 1995;2:281-289.
25. Kukowska-Latallo JF, Bielinska AU, Johnson J, et al. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA. 1996;93:4897-4902.
26. Schmidt D, Harms D, Burdach S. Malignant peripheral neuroectodermal tumours of childhood and adolescence. Virchows Arch (Pathol Anal). 1985;406:351-365.
27. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors: a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994;331:294-299.
28. Zucman J, Melot T, Desmaze C, et al. Combinatorial generation of variable fusion proteins in peripheral primitive neuroectodermal tumors. EMBO J 1993;12:4481-4487.
29. Giovanni M, Biegel JA, Serra M, et al. EWS-erg and EWS-FLI-1 fusion transcript in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest. 1994;94:489-496.
30. May WA, Gishizky ML, Lessnick SL, et al. Ewing's sarcoma 11;22 translocation encodes a chimeric transcription factor that requires DNA-binding domain of FLI-1 for transformation. Proc Natl Acad Sci USA. 1993;90:5752-5756.
31. + lymphocyte population following gene therapy with transgenic IL-2 secreting fibroblasts in a child with peripheral neuroectodermal malignancy. Med Pediatr Oncol. 1998;31:56-60.
32. BielinskaA, Kukowska-Latallo Johnson J, et al. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucl Acid Res. 1996;24:2176-2182.
33. Qin L, Pahud DR, Ding Y, et al. Efficient transfer of genes into murine cardiac grafts by Starburst polyamidoamine, dendrimers. Hum Gene Ther. 1998;9:553-560.
34. Gansbacher B, Zier K, Cronin K, et al. Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood. 1992;80:2817-2825.
35. Parker SE, Khatibi S, Margalith M, et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther. 1996;3:175-185.
36. Stopeck A, Hersh EM, Brailey JL, et al. Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. Cancer Gene Ther. 1998;5:119-126.
37. Comas MV, Basso S, Meazza R, et al. Characterization and tumorigenicity of human neuroblastoma cells transfected with the IL-2 gene. Cancer Gene Ther. 1997;5:38-44.
38. Porgador A, Gansbacher B, Bannerji R, et al. Anti-metastatic vaccination of tumor-bearing mice with the IL-2-gene-inserted tumor cells. Int J Cancer. 1993;53:471-477.
39. Fakhrai H, Shawler DL, Gjerset R, et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther. 1995;6:591-601.
40. Veelken H, Mackensen A, Lahn M, et al. A phase-I clinical study of autologous tumor cells plus interleukine-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer. 1997;70:269-277.